EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Ankylosing Spondylitis Patients Commencing Biologic Therapy Have High Baseline Levels of Comorbidity: A Report from the Australian Rheumatology Association Database

John Oldroyd, Lionel Schachna, Rachelle Buchbinder, Margaret Staples, Bridie Murphy, Molly Bond, Andrew Briggs, Marissa Lassere, Lyn March

International Journal of Rheumatology · 2009

DOI: 10.1155/2009/268569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Rheumatology, 2009. Verfasst von John Oldroyd und 8 weiteren Autor:innen. Beteiligte Einrichtung: Monash Department of Clinical Epidemiology, Cabrini Institute, 183 Wattletree Road, Malvern, VIC 3144, Australia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: National Health and Medical Research Council, Monash University, Wyeth.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To compare the baseline characteristics of a population-based cohort of patients with ankylosing spondylitis (AS) commencing biological therapy to the reported characteristics of bDMARD randomised controlled trials (RCTs) participants.

Methods

Descriptive analysis of AS participants in the Australian Rheumatology Association Database (ARAD) who were commencing bDMARD therapy.

Results

Up to December 2008, 389 patients with AS were enrolled in ARAD. 354 (91.0%) had taken bDMARDs at some time, and 198 (55.9%) completed their entry questionnaire prior to or within 6 months of commencing bDMARDs. 131 (66.1%) had at least one comorbid condition, and 24 (6.8%) had a previous malignancy (15 nonmelanoma skin, 4 melanoma, 2 prostate, 1 breast, cervix, and bowel). Compared with RCT participants, ARAD participants were older, had longer disease duration and higher baseline disease activity.

Conclusions

AS patients commencing bDMARDs in routine care are significantly different to RCT participants and have significant baseline comorbidities.

Autor:innen und Institutionen

  • Monash Department of Clinical Epidemiology, Cabrini Institute, 183 Wattletree Road, Malvern, VIC 3144, Australia.

Förderung

  • National Health and Medical Research Council
  • Monash University
  • Wyeth
  • Sanofi-Aventis Australia

Zitieren

APA

Oldroyd, J., Schachna, L., Buchbinder, R., Staples, M., Murphy, B., Bond, M., Briggs, A., Lassere, M., & March, L. (2009). Ankylosing Spondylitis Patients Commencing Biologic Therapy Have High Baseline Levels of Comorbidity: A Report from the Australian Rheumatology Association Database. International Journal of Rheumatology. https://doi.org/10.1155/2009/268569

Vancouver

Oldroyd J, Schachna L, Buchbinder R, Staples M, Murphy B, Bond M, et al. Ankylosing Spondylitis Patients Commencing Biologic Therapy Have High Baseline Levels of Comorbidity: A Report from the Australian Rheumatology Association Database. International Journal of Rheumatology. 2009. doi:10.1155/2009/268569

BibTeX
@article{Oldroyd2009,
  author = {Oldroyd, John and Schachna, Lionel and Buchbinder, Rachelle and Staples, Margaret and Murphy, Bridie and Bond, Molly and Briggs, Andrew and Lassere, Marissa and March, Lyn},
  title = {Ankylosing Spondylitis Patients Commencing Biologic Therapy Have High Baseline Levels of Comorbidity: A Report from the Australian Rheumatology Association Database},
  journal = {International Journal of Rheumatology},
  year = {2009},
  doi = {10.1155/2009/268569}
}
Kostenlos starten →